Search
Nuclear Medicine Pioneer Secures Over 300 Million Yuan in C+ Funding Round
2025-07-21 /
Read about 0 minute
Author：小编
Lanachen Biotechnology, a holding subsidiary of Dongcheng Pharmaceutical, has successfully closed a C+ round of financing exceeding 300 million yuan. This round was jointly invested by China Cinda, New Kinetic Energy Fund, and Dongcheng Pharmaceutical, with H Capital serving as the exclusive financial advisor. The procured funds will be allocated towards expediting the global clinical development and industrialization of Lanachen's innovative "theranostics" radiopharmaceutical pipeline.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
